Market capitalization | $328.75b |
Enterprise Value | $393.46b |
P/E (TTM) P/E ratio | 79.20 |
EV/FCF (TTM) EV/FCF | 25.57 |
EV/Sales (TTM) EV/Sales | 6.86 |
P/S ratio (TTM) P/S ratio | 5.73 |
P/B ratio (TTM) P/B ratio | 231.51 |
Dividend yield | 3.38% |
Last dividend (FY24) | $6.29 |
As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.
30 Analysts have issued a AbbVie forecast:
30 Analysts have issued a AbbVie forecast:
Mar '25 |
+/-
%
|
||
Revenue | 57,367 57,367 |
5%
5%
|
|
Gross Profit | 40,555 40,555 |
12%
12%
|
|
EBITDA | 25,808 25,808 |
5%
5%
|
EBIT (Operating Income) EBIT | 17,457 17,457 |
9%
9%
|
Net Profit | 4,155 4,155 |
30%
30%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Head office | United States |
CEO | Robert Michael |
Employees | 55,000 |
Founded | 2011 |
Website | www.abbvie.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.